Literature DB >> 16152568

Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia.

Mark D Brennan1, Jodi Condra.   

Abstract

Previous studies suggest a role for chromosome 22q13 in schizophrenia. This segment of chromosome 22 contains the sulfotransferase-4A1 (Sult4A1) gene, which encodes an enzyme thought to be involved in neurotransmitter metabolism in the central nervous system. To evaluate this candidate, we developed a microsatellite marker targeting a polymorphism in its 5' nontranslated region (D22s1749E). Using samples obtained from the National Institutes of Mental Health Schizophrenia Genetics Initiative, we evaluated 27 families having multiple siblings with schizophrenia and schizophrenia-spectrum disorders for transmission disequilibrium (TDT) of this marker along with three single nucleotide polymorphisms (SNPs) spanning a 37 kb segment containing the Sult4A1 gene. TDT for D22s1749E was significant (P < 0.05), with a tendency for the 213 nt allele to be preferentially transferred to affected children (P = 0.0079). Global chi-square values for haplotypes involving the SNPs (ss146366, ss146407, and ss146420) and D22s1749E, also showed significant TDT values (P = 0.0006-0.0016). Consequently, we proposed that Sult4A merited more careful scrutiny as a candidate gene for schizophrenia susceptibility. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16152568     DOI: 10.1002/ajmg.b.30222

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  6 in total

1.  Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.

Authors:  Timothy L Ramsey; Herbert Y Meltzer; Guy N Brock; Bharat Mehrotra; Karu Jayathilake; William V Bobo; Mark D Brennan
Journal:  Pharmacogenomics       Date:  2011-04       Impact factor: 2.533

2.  Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.

Authors:  Anirban Basu; Herbert Y Meltzer
Journal:  J Comp Eff Res       Date:  2012-03       Impact factor: 1.744

3.  SULT4A1 Modulates Synaptic Development and Function by Promoting the Formation of PSD-95/NMDAR Complex.

Authors:  Lorenza Culotta; Paolo Scalmani; Ersilia Vinci; Benedetta Terragni; Alessandro Sessa; Vania Broccoli; Massimo Mantegazza; Tobias Boeckers; Chiara Verpelli
Journal:  J Neurosci       Date:  2020-08-12       Impact factor: 6.167

4.  Generation and Characterization of SULT4A1 Mutant Mouse Models.

Authors:  Patrick L Garcia; Mohammed I Hossain; Shaida A Andrabi; Charles N Falany
Journal:  Drug Metab Dispos       Date:  2017-11-06       Impact factor: 3.922

Review 5.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

6.  Sulfotransferase 4A1 activity facilitates sulfate-dependent cellular protection to oxidative stress.

Authors:  Evan J Brettrager; Arthur W Meehan; Charles N Falany; Robert C A M van Waardenburg
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.